MX362664B - Antagonistas peptídicos del receptor de vasopresina 2. - Google Patents
Antagonistas peptídicos del receptor de vasopresina 2.Info
- Publication number
- MX362664B MX362664B MX2015003225A MX2015003225A MX362664B MX 362664 B MX362664 B MX 362664B MX 2015003225 A MX2015003225 A MX 2015003225A MX 2015003225 A MX2015003225 A MX 2015003225A MX 362664 B MX362664 B MX 362664B
- Authority
- MX
- Mexico
- Prior art keywords
- vasopressin
- receptor
- peptide antagonists
- diagnosis
- therapy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La invención se refiere a una proteína aislada, que comprende una secuencia de aminoácido la cual es por lo menos 70% idéntica a los residuos a 1 57 de SEQ ID NO: 1 y la cual comprende: (i) un motivo X1X2X3X4 en las posiciones a 15 a 18 de SEQ ID NO: 1, en donde X1 es una asparagina (N) X2 es una glicina (G), X3,y X4 son aminoácidos hidrofóbicos, y (ii) uno hasta tres enlaces de disulfuro entre dos residuos cisteína, para usarse como antagonista del receptor de vasopresina 2 (V2R) en el tratamiento de enfermedades seleccionadas del grupo que consiste en condiciones patológicas seleccionadas de hiponatremia euvolémica o hipovolémica, síndrome nefrogénico de antidiuresis inapropiada, diabetes insípida nefrogénica congénita, enfermedad renal poliquística, cánceres, trombosis, y enfermedad de Méiere.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12306120.2A EP2708235A1 (en) | 2012-09-17 | 2012-09-17 | Peptide antagonists of the vasopressin-2 receptor |
| PCT/IB2013/058615 WO2014041526A1 (en) | 2012-09-17 | 2013-09-17 | Peptide antagonists of the vasopressin-2 receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015003225A MX2015003225A (es) | 2015-11-16 |
| MX362664B true MX362664B (es) | 2019-01-31 |
Family
ID=46963639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015003225A MX362664B (es) | 2012-09-17 | 2013-09-17 | Antagonistas peptídicos del receptor de vasopresina 2. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9631001B2 (es) |
| EP (2) | EP2708235A1 (es) |
| JP (1) | JP6392758B2 (es) |
| KR (1) | KR102135954B1 (es) |
| CN (1) | CN104684574B (es) |
| AU (1) | AU2013316700B2 (es) |
| BR (1) | BR112015005750B1 (es) |
| CA (1) | CA2884361C (es) |
| DK (1) | DK2895189T3 (es) |
| ES (1) | ES2664747T3 (es) |
| MX (1) | MX362664B (es) |
| NZ (1) | NZ706202A (es) |
| RU (1) | RU2015114320A (es) |
| WO (1) | WO2014041526A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020006179A1 (en) * | 2018-06-28 | 2020-01-02 | Salaqua Diagnostics, Inc. | Compositions and methods associated with haptoglobin related protein |
| EP3929209A1 (en) | 2020-06-24 | 2021-12-29 | Commissariat à l'Energie Atomique et aux Energies Alternatives | Vasopressin-2 receptor antagonist peptides and uses thereof |
| CN115820734A (zh) * | 2022-11-11 | 2023-03-21 | 北京希诺谷生物科技有限公司 | 中枢性尿崩症疾病模型犬的建立方法 |
| CN116425888A (zh) * | 2023-04-24 | 2023-07-14 | 徐州医科大学 | 一种多肽tat-v2r1c及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663143A (en) * | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
| SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| WO2007019267A1 (en) | 2005-08-03 | 2007-02-15 | Mineuet Therapeutics Ltd. | MODULATING THE KV1.1 VOLTAGE-GATED POTASSIUM CHANNEL IN T-CELLS FOR REGULATING THE SYNTHESIS AND SECRETION OF TUMOR NECROSIS FACTOR α (TNF-α) AND TREATING HUMAN DISEASES OR INJURIES MEDIATED BY DETRIMENTALLY HIGH OR LOW LEVELS OF TNF-α |
| WO2009149339A2 (en) | 2008-06-05 | 2009-12-10 | University Of Maryland, Baltimore | P53 activator peptides |
-
2012
- 2012-09-17 EP EP12306120.2A patent/EP2708235A1/en not_active Withdrawn
-
2013
- 2013-09-17 WO PCT/IB2013/058615 patent/WO2014041526A1/en active Application Filing
- 2013-09-17 CN CN201380048382.9A patent/CN104684574B/zh active Active
- 2013-09-17 AU AU2013316700A patent/AU2013316700B2/en active Active
- 2013-09-17 RU RU2015114320A patent/RU2015114320A/ru not_active Application Discontinuation
- 2013-09-17 KR KR1020157009903A patent/KR102135954B1/ko active IP Right Grant
- 2013-09-17 ES ES13801742.1T patent/ES2664747T3/es active Active
- 2013-09-17 DK DK13801742.1T patent/DK2895189T3/en active
- 2013-09-17 MX MX2015003225A patent/MX362664B/es active IP Right Grant
- 2013-09-17 EP EP13801742.1A patent/EP2895189B1/en active Active
- 2013-09-17 US US14/427,733 patent/US9631001B2/en active Active
- 2013-09-17 NZ NZ706202A patent/NZ706202A/en unknown
- 2013-09-17 JP JP2015531678A patent/JP6392758B2/ja active Active
- 2013-09-17 CA CA2884361A patent/CA2884361C/en active Active
- 2013-09-17 BR BR112015005750-0A patent/BR112015005750B1/pt active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015005750B1 (pt) | 2022-08-16 |
| ES2664747T3 (es) | 2018-04-23 |
| US9631001B2 (en) | 2017-04-25 |
| WO2014041526A1 (en) | 2014-03-20 |
| DK2895189T3 (en) | 2018-04-16 |
| US20150252086A1 (en) | 2015-09-10 |
| EP2895189A1 (en) | 2015-07-22 |
| CA2884361A1 (en) | 2014-03-20 |
| BR112015005750A2 (pt) | 2017-12-12 |
| CN104684574A (zh) | 2015-06-03 |
| CN104684574B (zh) | 2018-08-31 |
| AU2013316700A1 (en) | 2015-04-09 |
| JP2016500001A (ja) | 2016-01-07 |
| KR20150070172A (ko) | 2015-06-24 |
| EP2708235A1 (en) | 2014-03-19 |
| MX2015003225A (es) | 2015-11-16 |
| EP2895189B1 (en) | 2018-01-10 |
| JP6392758B2 (ja) | 2018-09-19 |
| BR112015005750A8 (pt) | 2018-04-17 |
| KR102135954B1 (ko) | 2020-07-21 |
| AU2013316700B2 (en) | 2017-10-12 |
| RU2015114320A (ru) | 2016-11-10 |
| CA2884361C (en) | 2022-03-22 |
| NZ706202A (en) | 2018-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT201700021B (it) | Metodi per il trattamento di malattie autoimmuni con antagonisti del dll4 | |
| IL265774B (en) | Diagnosis, prevention and treatment of joint diseases | |
| PH12014501844B1 (en) | Peptidomimetic macrocycles | |
| EP3091074A4 (en) | T cell receptor and b cell receptor repertoire analysis system, and use of same in treatment and diagnosis | |
| HK1207304A1 (en) | Crhr1 antagonists for use in the treatment of patients having crh overactivity crh crhr1 | |
| MX355543B (es) | Macrociclos peptidomiméticos. | |
| IL231378A0 (en) | Prongs of tubes, rings for connecting tissues and methods of supplying and using them | |
| IL239390A0 (en) | Analogues of pyridonemorphine and biological activity at opioid receptors | |
| EP2832083A4 (en) | SYSTEMS AND METHODS FOR CALL MATCHING USING AVERAGE BAYESIAN REGRESSION (BMR) | |
| UA115231C2 (uk) | Сполуки імідазопіролідинонів | |
| TN2012000414A1 (en) | Forms of rifaximin and uses thereof | |
| IL229299A0 (en) | Integrin receptor antagonists for use in therapeutic or diagnostic applications | |
| HK1199401A1 (en) | Pharmaceutical formulations and the use thereof for the treatment of peanut allergy | |
| EA201390977A1 (ru) | Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона | |
| SG11201403756PA (en) | Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents | |
| EP2709991A4 (en) | USE OF CXCR4 ANTAGONISTS | |
| DK2900279T3 (da) | Grpr-antagonister til detektering, diagnose og behandling af grpr-positiv cancer | |
| ES2446643R1 (es) | Composiciones farmacéuticas combinadas y su uso para preparar un medicamento destinado al tratamiento del vértigo, la cinetosis y la distonía vegetativa-vascular | |
| EP3628326C0 (en) | METHODS AND SUBSTANCES FOR TREATING PUMP DISEASE | |
| EP2548888A4 (en) | SPECIFIC PEPTIDE OF PERIODONTAL PATHOLOGY AND TREATMENT AND DIAGNOSIS OF PERIODONTAL PATHOLOGY INCLUDING | |
| EA201400623A1 (ru) | Новые 2h-индазолы в качестве антагонистов рецептора ep | |
| PH12017502099A1 (en) | Methods for diagnosing and assessing treatment for cushing's syndrome | |
| MX362664B (es) | Antagonistas peptídicos del receptor de vasopresina 2. | |
| EP2802339A4 (en) | USE OF CYCLIC PEPTIDES FROM LOINSEAMES TO IMPROVE THE HEALTH OF ANIMAL AND MAN | |
| GB201210686D0 (en) | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FG | Grant or registration |